DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Cancer Pain - Pipeline Review, H1 2016" drug pipelines to their offering.
The report provides comprehensive information on the therapeutics under development for Cancer Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cancer Pain and features dormant and discontinued projects.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope:
- The report provides a snapshot of the global therapeutic landscape of Cancer Pain
- The report reviews pipeline therapeutics for Cancer Pain by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Cancer Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Cancer Pain
Companies Mentioned:
- AngioChem Inc.
- Aphios Corporation
- AstraZeneca Plc
- BCN Peptides, S.A.
- Benitec Biopharma Limited
- BioDelivery Sciences International, Inc.
- ChironWells GmbH
- Daewoong Pharmaceutical Co., Ltd.
- Daiichi Sankyo Company, Limited
- Fujimoto Pharmaceutical Corporation
- Grunenthal GmbH
- GW Pharmaceuticals Plc
- Hisamitsu Pharmaceutical Co., Inc.
- Immupharma Plc
- IntelGenx Corp.
- Kineta, Inc.
- Kolon Life Science, Inc.
- Neurocentrx Pharma Ltd.
- Nippon Kayaku Co., Ltd.
- Orion Oyj
- Pain Therapeutics, Inc.
- Pfizer Inc.
- Pharmaleads SA
- Recordati S.p.A.
- Ribomic Inc.
- Trillium Therapeutics Inc.
- Virobay Inc.
- WEX Pharmaceuticals Inc.
- Zynerba Pharmaceuticals, Inc.
For more information visit http://www.researchandmarkets.com/research/c2r3ds/cancer_pain
